X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (263) 263
Publication (70) 70
Book Chapter (5) 5
Book / eBook (3) 3
Book Review (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (109) 109
humans (102) 102
melanoma (87) 87
ipilimumab (80) 80
immunotherapy (72) 72
oncology (72) 72
melanoma - drug therapy (53) 53
female (50) 50
male (50) 50
article (49) 49
cancer (47) 47
middle aged (43) 43
aged (42) 42
metastatic melanoma (42) 42
adult (37) 37
antibodies, monoclonal - therapeutic use (37) 37
care and treatment (35) 35
survival (32) 32
aged, 80 and over (30) 30
nivolumab (30) 30
metastasis (27) 27
melanoma - pathology (25) 25
patients (24) 24
skin neoplasms - drug therapy (24) 24
abridged index medicus (22) 22
antibodies, monoclonal - adverse effects (22) 22
pembrolizumab (22) 22
melanoma - immunology (20) 20
tumors (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
drug therapy (19) 19
research (19) 19
retrospective studies (19) 19
ctla-4 (18) 18
ctla-4 blockade (18) 18
immunology (18) 18
programmed cell death 1 receptor - antagonists & inhibitors (18) 18
ctla-4 antigen - antagonists & inhibitors (17) 17
treatment outcome (17) 17
skin neoplasms - pathology (16) 16
antineoplastic agents - adverse effects (15) 15
antineoplastic agents - therapeutic use (15) 15
cancer therapies (15) 15
immunotherapy - methods (15) 15
lymphocytes (15) 15
pd-1 (15) 15
prognosis (15) 15
programmed cell death 1 receptor - immunology (15) 15
animals (14) 14
clinical trials (14) 14
medicine, general & internal (14) 14
neoplasms - immunology (14) 14
t cells (14) 14
antibodies, monoclonal - administration & dosage (13) 13
ctla-4 antigen - immunology (13) 13
lymphocytes t (13) 13
melanoma - mortality (13) 13
open-label (13) 13
therapy (13) 13
usage (13) 13
young adult (13) 13
biomarkers (12) 12
cell biology (12) 12
cytotoxicity (12) 12
dosage and administration (12) 12
medical research (12) 12
medicine, research & experimental (12) 12
melanoma - therapy (12) 12
untreated melanoma (12) 12
chemotherapy (11) 11
immune checkpoint (11) 11
melanoma - secondary (11) 11
metastases (11) 11
radiotherapy (11) 11
safety (11) 11
anti-pd-1 (10) 10
antibodies (10) 10
neoplasm staging (10) 10
neoplasms - drug therapy (10) 10
studies (10) 10
vemurafenib (10) 10
antibody (9) 9
cell lung-cancer (9) 9
combined modality therapy (9) 9
disease-free survival (9) 9
health aspects (9) 9
immune system (9) 9
medicine (9) 9
mutation (9) 9
mutations (9) 9
neoplasms - therapy (9) 9
advanced melanoma (8) 8
analysis (8) 8
antigens (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
antitumor immunity (8) 8
apoptosis (8) 8
b7-h1 antigen - antagonists & inhibitors (8) 8
cytotoxic t-lymphocyte antigen 4 (8) 8
diagnosis (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1345 - 1356
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 1, pp. 23 - 34
Journal Article
Book
by Amaria, Rodabe N and Menzies, Alexander M and Burton, Elizabeth M and Scolyer, Richard A and Tetzlaff, Michael T and Antdbacka, Robert and Ariyan, Charlotte and Bassett, Roland and Carter, Brett and Daud, Adil and Faries, Mark and Fecher, Leslie A and Flaherty, Keith T and Gershenwald, Jeffrey E and Hamid, Omid and Hong, Angela and Kirkwood, John M and Lo, Serigne and Margolin, Kim and Messina, Jane and Postow, Michael A and Rizos, Helen and Ross, Merrick I and Rozeman, Elisa A and Saw, Robyn P M and Sondak, Vernon and Sullivan, Ryan J and Taube, Janis M and Thompson, John F and van de Wiel, Bart A and Eggermont, Alexander M and Davies, Michael A and Andrews, Miles C and Berry, Donald A and Block, Matthew S and Boland, Genevieve M and Bollin, Kathryn B and Carlino, Matteo S and Carvajal, Richard D and Cohen, Jonathan and Davar, Diwakar and Delman, Keith A and Dummer, Reinhard and Farwell, Michael D and Fisher, David E and Fusi, Alberto and Glitza, Isabella C and de Gruijl, Tanja D and Gyorki, David E and Hauschild, Axel and Hieken, Tina J and Larkin, James and Lawson, David H and Lebbe, Celeste and Lee, Jeffrey E and Lowe, Michael C and Luke, Jason J and McArthur, Grant A and McDermott, David F and McQuade, Jennifer L and Mitchell, Tara C and Petrella, Teresa M and Prieto, Peter A and Puzanov, Igor and Robert, Caroline and Salama, April K and Sandhu, Shaneen and Schadendorf, Dirk and Shoushtari, Alexander N and Sosman, Jeffrey A and Swetter, Susan M and Tanabe, Ken K and Turajlic, Samra and Tyler, Douglas S and Woodman, Scott E and Wright, Frances C and Zager, Jonathan S and Ascierto, Paolo A and Spillane, Andrew J and van Akkooi, Alexander C J and Wargo, Jennifer A and Blank, Christian U and Tawbi, Hussein A and Long, Georgina V and Int Neoadjuvant Melanoma and International Neoadjuvant Melanoma Consortium members
The Lancet Oncology, ISSN 1470-2045, 07/2019, Volume 20, Issue 7, pp. e378 - e389
Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to... 
SURVIVAL | PREOPERATIVE CHEMOTHERAPY | RESPONSE CRITERIA | ONCOLOGY | IMMUNOTHERAPY | TRAMETINIB | ADJUVANT DABRAFENIB | DISEASE | GUIDELINES | STAGE-III | BREAST | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Melanoma | Cancer
Journal Article
The Lancet Oncology, ISSN 1470-2045, 09/2017, Volume 18, Issue 9, pp. 1144 - 1145
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9948, pp. 1109 - 1117
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2018, Volume 379, Issue 8, pp. 722 - 730
Journal Article
Pharmacogenomics and Personalized Medicine, ISSN 1178-7066, 11/2014, Volume 7, pp. 357 - 365
T-lymphocytes have the potential to recognize cancer antigens as foreign and therefore eliminate them. However, immune checkpoints such as cytotoxic... 
Immune checkpoints | Cytotoxic T-lymphocyte antigen 4 | Programmed cell death protein-1 | Immunotherapy | Care and treatment | Cell death | Innovations | Genetic aspects | Health aspects | Cancer | Antigens | Dendritic cells | Cytokines | Melanoma | Homeostasis | Cytotoxicity | Vaccines | Metastasis | FDA approval | Cancer therapies | Skin cancer | Lymphocytes | Biomarkers | Ligands | Lymphomas | Immune system | Apoptosis
Journal Article